DE NOVO TINF2 C.845G>A: PATHOGENIC VARIANT
IN PATIENT WITH DYSKERATOSIS CONGENITA
Kocheva SA, Gjorgjievska M, Martinova K, Antevska-Trajkova Z,
Jovanovska A, Plaseska-Karanfilska D
*Corresponding Author: Svetlana Kocheva, MD, PhD, Department of Hematology and Oncology
Children’s Diseases, Majka Tereza 17, Skopje, North Macedonia, tel. +38971378184
e-mail: dr.kocheva@gmail.com
page: 89
|
|
REFERENCES
1. Walne AJ, Marrone A, Dokal I: Dyskeratosis congenita:
a disorder of defective telomere maintenance? Int
J Hematol 2005; 82:184–189.
2. Dokal I. Dyskeratosis congenita in all its forms. Br
J Haematol. 2000; 110: 768-779.
3. Bessler M, Wilson DB, Mason PJ. Dyskeratosis congenita.
FEBS Lett. 2010; 584: 3831-3838.
4. Ballew BJ, Savage SA. Updates on the biology and
management of dyskeratosis congenita and related
telomere biology disorders. Expert Rev Hematol.
2013; 6: 327–37.
5. Alter BP, Giri N, Savage SA, Rosenberg PS. Cancer in
dyskeratosis congenita. Blood. 2009; 113(26): 6549-57.
6. Heiss NS, Knight SW, Vulliamy T, SM Klauck, S
Wiemann, P J Mason et al. X-linked dyskeratosis congenita
is caused by mutations in a highly conserved gene with putative nucleolar functions. Nat Genet.
1998; 19: 32-38.
7. Walne AJ, Dokal I: Advances in the understanding
of dyskeratosis congenita. Br J Haematol. 2009; 145:
164-172.
8. Savage SA, Giri N, Baerlocher GM, Orr N, Lansdorp
PM, Alter BP: TINF2, a component of the shelterin
telomere protection complex, is mutated in dyskeratosis
congenita. Am J Hum Genet. 2008; 82: 501-509.
9. Calado RT (ed): Progress in Molecular Biology and
Translational Science, ed 1. Waltham, Academic
Press, 2014.
10. Du HY, Mason PJ, Bessler M, and Wilson DB. Pediatr.
Blood Cancer. 2009; 52: 687.
11. Tsangaris E, Adams SL, Yoon G, Chitayat D, Lansdorp
P, Dokal I, and Dror Y. Hum. Genet. 2008; 124: 507-513.
12. Walne AJ, Vulliamy T, Beswick R, Michael K, Dokal
I. TINF2 mutations result in very short telomeres:
analysis of a large cohort of patients with dyskeratosis
congenita and related bone marrow failure syndromes.
Blood. 2008; 112(9): 3594–3600.
13. Sarper N, Zengin E, Kilic SC. A child with severe
form of dyskeratosis congenita and TINF2 mutation
of shelterin complex. Pediatr Blood Cancer. 2010;
55(6):1185–1186.
14. Fukuhara A, Tanino Y, Ishii T, Inokoshi Y, Saito K,
Fukuhara N et al. Pulmonary fibrosis in dyskeratosis
congenita with TINF2 gene mutation. Eur Respir J.
2013; 42: 1757–1759.
15. Savage SA. Dyskeratosis Congenita. 2009 Nov 12
[updated 2019 Nov 21]. In: Adam MP, Ardinger HH,
Pagon RA, Wallace SE, Bean LJH, Mirzaa G, Amemiya
A, editors. GeneReviews® [Internet]. Seattle
(WA): University of Washington, Seattle; 1993-2021.
Available from http://www.ncbi.nlm.nih.gov/books/
NBK22301/ Citation on PubMed
16. Karremann M, Neumaier-Probst E, Schlichtenbrede
F, Beier F, Brümmendorf TH, et al. Revesz syndrome
revisited. Orphanet J Rare Dis. 2020; 15: 299.
17. Hongchun D, Yubiao G, Di M, Kejing T, Decheng C,
et al. A case report of heterozygous TINF2 gene mutation
associated with pulmonary fibrosis in a patient
with dyskeratosis congenita. Medicine (Baltimore).
2018; 97(19): e0724.
18. Vulliamy T, Beswick R, Kirwan MJ, Hossain U,
Walne AJ, and Dokal I. Telomere length measurement
can distinguish pathogenic from non-pathogenic variants
in the shelterin component, TINF2. Clin Genet.
2012; 81(1): 76-81.
19. Sasa GS, Ribes-Zamora A. Nelson ND, Bertuch AA.
Three novel truncating TINF2 mutations causing severe
dyskeratosis congenita in early childhood. Clin
Genet. 2012; 81(5): 470-8.
20. Gutierrez-Rodrigues F, Donaires FS, Pinto A, Vicente
A, Dillon LW et al. Pathogenic TERT promoter variants
in telomere diseases. Genet Med. 2019; 21(7):
1594-1602.
21. Yang D, He Q, Kim H, Ma W, Songyang Z. TIN2
protein dyskeratosis congenita missense mutants are
defective in association with telomerase. J Biol Chem.
2011; 286 (26): 23022-30.
22. Li F, Li W, Qiao X, Xie X. Clinical features of dyskeratosis
congenita in mainland China: case reports
and literature review. Int J Hematol. 2019; 109(3):
328-335.
23. Pereboeva L, Hubbard M, Goldman FD, Westin ER.
Robust DNA Damage Response and Elevated Reactive
Oxygen Species in TINF2-Mutated Dyskeratosis
Congenita Cells. PLoS One. 2016; 11(2): e0148793.
24. Nelson ND, Dodson LM, Escudero L, Sukumar AT,
Williams CL, Mihalek I, et al. The C-Terminal Extension
Unique to the Long Isoform of the Shelterin
Component TIN2 Enhances Its Interaction with TRF2
in a Phosphorylation and Dyskeratosis Congenita
Cluster-Dependent Fashion. Mol Cell Biol. 2018;
38(12): e00025-18.
25. Norberg A, Rosén A, Raaschou-Jensen K, Kjeldsen
L, Moilanen JS, Paulsson-Karlsson Y, et al. Novel
variants in Nordic patients referred for genetic testing
of telomere-related disorders. Eur J Hum Genet.
2018; 26(6): 858-867.
26. Moussa K, Huang JN, Moore AT. Revesz syndrome
masquerading as traumatic retinal detachment. J AAPOS.
2017; 21(5): 422-425.
27. Monoi A, Sugawa M, Kato M, Seki M, Yoshida K,
Shiraishi Y, et al. Atypical dyskeratosis congenita
diagnosed using whole-exome sequencing. Pediatr
Int. 2017; 59(8): 933-935.
28. Guidugli L, Johnson AK, Alkorta-Aranburu G,
Nelakuditi V, Arndt K, Churpek JE, L at all. A Godley,
D Townsley, N S Young, C Fitzpatrick, D Del
Gaudio, S Das 1, Z Li 1. Clinical utility of gene
panel-based testing for hereditary myelodysplastic
syndrome/acute leukemia predisposition syndromes.
Leukemia. 2017; 31(5): 1226-1229.
29. Tomcikova D, Gerinec A, Busanyova B, Gresikova
M, Biskup S, Kortnagel K. Why is it necessary to
examine retina when the patient suffers from aplastic
anemia? Bratisl Lek Listy. 2018;119(5): 275-277.
|
|
|
|
 |
Number 27
VOL. 27 (2), 2024 |
Number 27
VOL. 27 (1), 2024 |
Number 26
Number 26 VOL. 26(2), 2023 All in one |
Number 26
VOL. 26(2), 2023 |
Number 26
VOL. 26, 2023 Supplement |
Number 26
VOL. 26(1), 2023 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
